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Chronic obstructive pulmonary disease affects 10% of the world-
wide population, and the leading genetic cause is α-1 antitrypsin
(AAT) deficiency. Due to the complexity of the murine locus, which
includes up to six Serpina1 paralogs, no genetic animal model of the
disease has been successfully generated until now. Here we create
a quintuple Serpina1a–e knockout using CRISPR/Cas9-mediated ge-
nome editing. The phenotype recapitulates the human disease phe-
notype, i.e., absence of hepatic and circulating AAT translates
functionally to a reduced capacity to inhibit neutrophil elastase. With
age, Serpina1 null mice develop emphysema spontaneously, which
can be induced in younger mice by a lipopolysaccharide challenge.
This mouse models not only AAT deficiency but also emphysema and
is a relevant genetic model and not one based on developmental
impairment of alveolarization or elastase administration. We antici-
pate that this unique model will be highly relevant not only to the
preclinical development of therapeutics for AAT deficiency, but also
to emphysema and smoking research.
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Chronic obstructive pulmonary disease (COPD) is the thirdleading cause of mortality worldwide (1), and it affects about
10% of the world population (2). While cigarette smoking and
exposure to air particulates are well-characterized environmental
risk factors, α-1 antitrypsin (AAT) deficiency is the most com-
mon known genetic factor (3). AAT deficiency is characterized
by mutations in the SERine Proteinase Inhibitor family A
member 1 (SERPINA1) gene. These mutations result in reduced
or inexistent levels of serum AAT protein (4), a protease in-
hibitor whose physiological target is neutrophil elastase (NE).
Low or no serum AAT therefore results in the unopposed action
of neutrophil elastase on the alveolar interstitium thereby leading
to destruction of the alveolar walls and lung parenchyma. Clini-
cally, this results in pulmonary emphysema, which is character-
ized by fewer, larger air sacs with less recoil and decreased gas
exchange, leading to increasing breathlessness.
The current standard of care is weekly or biweekly intravenous
infusion of recombinant AAT protein. Unfortunately, because
this disease is underdiagnosed, many patients start treatment
after their respiratory function is significantly and irreversibly
compromised. In addition, lifelong weekly or biweekly infu-
sions remain a burden for patients, and alternative therapeutic
options allowing for less frequent interventions are being actively
investigated, including gene therapy (5–8) and genome editing (9).
However, the development of new therapeutics is hindered by the
absence of an animal model (10). Current study goals for protein
replacement therapies are based on the FDA-defined endpoint of
11 μM serum AAT and not on a physiologically relevant endpoint
such as respiratory measurements, which may limit approval of
functional candidates. The absence of a mouse model is due to the
presence of Serpina1 paralogs in the murine genome (11), which
made the generation of a full knockout a very difficult target using
traditional methods. In addition, some reports have dissuaded these
efforts due to the possibility of an embryonic role for these genes in
mice. In fact a murine Serpina1a knockout was recently described to
be embryonically lethal (12), as well as a murine Serpina1b knockout
(13). However, it is unclear why mice not only amplified the gene
but also developed an embryonic role for it and why deleting only
one of several highly similar murine paralogs would be lethal while
SERPINA1 null humans are viable. Prompted by this incongruity
and the advent of CRISPR technology, we sought to confirm these
surprising findings by generating a full knockout using guide RNAs
(gRNAs) that target a sequence in exon 2 that is conserved in all
Serpina1 genes. Here, we demonstrate the successful generation of a
murine complete Serpina1a–e knockout with biallelic editing of five
genes in a single round of zygote injections. This mouse model has a
normal lifespan but presents with a respiratory phenotype that
recapitulates many aspects of the human disease and therefore
constitutes a true and robust model in which to validate novel
therapeutics and investigate the biology of emphysema.
Results
Generation of the Serpina1a–e Knockout.Due to gene amplification
events, six Serpina1 genes exist in the murine genome. These are
designated in the current nomenclature as Serpina1a through
Serpina1f, although only Serpina1a–e are expressed in the liver.
The genes are 11 kb long and span about 230 kb on chromosome
12. In our mouse strain of choice, C57BL/6J, those five Serpina1
genes (a–e) are present and expressed (11). The corresponding
proteins are designated as α-1 antitrypsin (AAT) 1-1 through 1-5.
Of these, AAT 1-1 and AAT 1-2 inhibit both neutrophil and
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pancreatic elastases, while AAT 1-3 and AAT 1-4 do not, and AAT
1-5 is not well characterized (14). Four gRNAs were designed in a
region conserved in all Serpina1 paralogs, exon 2 (Fig. 1A), and
validated in vitro with a GFP-based single strand annealing assay.
Genetically modified mice were generated using previously de-
scribed methods (15). Briefly, zygotes were microinjected with
Cas9 mRNA and all four gRNAs, and subsequently implanted in
13 pseudopregnant females. A total of 45 pups were born, of which
87% survived weaning (Fig. 1B) and their sera was screened for
total murine AAT load by ELISA using a polyclonal antibody. Out
of the 39 viable animals, 3 were identified as complete biallelic
Serpina1a–e knockouts due to no detectable expression of AAT
(Fig. 1C), two males and one female (subsequently referred to as
#7, #24, and #31). Germline transmission was demonstrated when
crossing founders #7 and #31 led 100% of the progeny to have
undetectable levels of circulating AAT (Fig. 1D). To get rid of
hypothetical undesired genomic alterations due to CRISPR-related
off-target effects, founders #7 and #24 were independently back-
crossed three times (Fig. 1E) and founder #31 has currently been
backcrossed twice. This led to the generation of three independent
lines of Serpina1a–e knockouts subsequently referred to as 7A, 24B,
and 31C for founders #7, #24, and #31, respectively. Genetic
linkage of the disrupted alleles was demonstrated when the first
backcross of founders #7 and #24 led to a 100% heterozygous
progeny (Fig. 1F), as determined by AAT serum levels. Serpina1a–e
knockout mice have a normal lifespan, ability to breed, and
gender distribution.
Phenotypic and Functional Characterization. AAT is produced in the
liver, secreted in the bloodstream, and eventually reaches the lungs,
which is its main site of action. In the lungs, AAT protects the lung
alveoli and interstitial elastin from destruction by inactivating
neutrophil elastase. To assess whether the protein was present in
the circulation, blood serum was sampled and analyzed by Western
blot using an antimouse AAT primary antibody. The three founders
demonstrated undetectable levels of AAT (Fig. 1G), confirming the
results of the initial ELISA screening (Fig. 1C). Next, liver sections
were subjected to immunohistochemical staining. While a strong
staining reflects the high abundance of hepatic AAT in wild-type
mice, the Serpina1a–e knockout mice revealed a complete lack of
staining, denoting absence of the protein (Fig. 1H). Finally, we
assessed the biochemical consequences of the lack of circulating
AAT by analyzing the ability of the sera to neutralize elastase ac-
tivity. Blood serum was incubated with elastase and an analog
chemical substrate, and relative elastase activity was derived from a
colorimetric quantification of the kinetics of substrate degradation.
While serum from wild-type male and female C57BL/6 mice
exhibited a high capacity to inhibit elastase, sera from the three
founders showed a reduced capacity to do so (Fig. 1I, red bars). The
reduced capacity of the serum samples from the three founders to
inhibit elastase was similar to the results obtained when using a
commercial elastase inhibitor (Fig. 1I, black bar). This indicates that
absence of serum AAT shown in Fig. 1 C and G translates to a loss
of its physiological antielastase function. Any remaining antielastase
activity in the sera of the founders might be due to other serum
serine proteinase inhibitors (serpins) with antielastase activity.
Genomic and Transcriptomic Characterization. Genomic editing al-
terations were characterized by targeted sequencing. Briefly, high
molecular weight genomic DNA (gDNA) was isolated from liver
tissue of one mouse per founder line. This gDNA was subsequently
sheared to a size of ∼6 kb, and fragments of interest were captured
using probes specific to the 230-kb region of interest (Fig. 1A). The
∼2-kb captured fragments were sequenced by long-read PacBio
sequencing, to allow for discrimination between highly homologous
Serpina1 paralogs. Analysis revealed excisions of up to 90 kb in lines
7A and 24B, and up to 76 kb in line 31C (Fig. 2 and Figs. S1–S3). In
line 24B, complementary targeted locus amplification (TLA) se-
quencing revealed a small excision of 73 bp in Serpina1b, at the
location of gRNA#2 (Figs. S5 and S6).
To confirm the excisions and nonsense-mediated decay (NMD)-
causing frameshifts, RNA was isolated from liver tissue of two
of the three founder lines for a transcriptome analysis. Four
mice from the F4 generation of line 7A and four mice from the
Fig. 1. Generation of the Serpina1 knockout. (A) The five Serpina1 genes span a 230-kb region on chromosome 12 and their 11-kb sequence is highly
homologous. Guide RNAs (gRNAs) were designed to target a conserved region in exon 2. (B) Statistics on the knockout generation from zygote injection to iden-
tification of the knockout line founders. (C) Pups were screened by murine AAT ELISA, and the three founders #7, #24, and #31 were identified by undetectable
protein levels, indicated by red arrows. −, negative control. (D) Breedingmale founder #7 with female founder #31 resulting in 100% of the progeny being knockouts,
as determined by serum AAT ELISA, demonstrated germline transmission. (E) Three independent founder lines were generated by backcrossing: line 7A from founder
#7, line 24B from founder #24, and line 31C from founder #31 (line 31C is currently at F4 only). (F) Backcrossing male founders #7 and #24 resulting in 100% of the
progeny being heterozygous, as determined by serum AAT ELISA, demonstrated genetic linkage (pups 45–67, line 7A; pups 69–86, line 24B; −, negative control; C57F,
wild-type mouse, positive control). The serum of the three founders is devoid from AAT protein, as confirmed by Western blot (G). (H) Immunohistochemistry shows
absence of AAT in liver tissue from knockout animals. These representative images show hepatocytes surrounding a blood vessel. (Scale bar, 100 μm.) (I) Serum from
the three founders has reduced antielastase activity, as determined by quantification of elastase activity. The − inhibitor bar is an internal assay control representing an
uninhibited reaction, and its value is normalized at 100. C57M, male wild-type mouse; 7M, male founder #7; 24M, male founder #24; 31F, female founder #31; C57F,
female wild-type mouse; and AAT control, commercial pooled mouse serum.
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F4 generation of line 24B, were compared with five C57BL/6
mice (all mice were 10-wk-old males) by RNA-Seq [single-end
50 base pair (bp) reads]. Founder #31 being female, the 31C line
is at an earlier generation and was therefore not included in this
analysis; however, preliminary data from a single animal do show
a significant reduction of transcripts for all five paralogs (Dataset
S1). RNA-Seq generated >50 million clean reads for each
sample. A total of 231 genes were dysregulated in line 7A:
126 up-regulated genes and 105 down-regulated genes (Fig. 3A).
A total of 299 genes were dysregulated in line 24B: 133 up-
regulated genes and 166 down-regulated genes (Fig. 3B). The
Serpina1 genes were the top down-regulated genes in both 7A
and 24B lines (Datasets S2 and S3). The only exception to this
was Serpina1b in line 24B. Reads mapping to Serpina1b were not
decreased (fold change 0.9916; adjusted P value 0.9869). How-
ever, analysis of the reads revealed a deletion of two bases at
position 314–315 of the mRNA, and additional deletions of four
bases at position 347–350 and nine bases at position 351–359.
These deletions overlap with the 73-bp genomic excision reported
above, which corresponds to position 320–353 of the mRNA.
Taken together with the genomic data, this suggests a combi-
nation of genomic excision events along gene disruptions resulting
in unstable or truncated transcripts. In total, 106 genes were
dysregulated in line 7A and line 24B jointly, 48 were up-regulated
(marked in red, Fig. 3C) and 58 were down-regulated (marked in
green, Fig. 3C and Dataset S4) including four of the Serpina genes
(a–c–d–e). Pathway analysis revealed that the top dysregulated
pathways were monocarboxylic acid and fatty acid metabolic
processes, rhythmic process and circadian rhythm for line A7 (Fig.
3D), and rhythmic process and circadian rhythm for line 24B
(Fig. 3E).
Off-targets for all four gRNAs were predicted using two in-
dependent algorithms: Cas OFFinder (16) and COSMID (17),
and all results were compiled in Datasets S5 and S6. Results
from these predictions were cross-referenced with the list of
dysregulated genes (Datasets S2 and S3). No predicted off-target
genes were identified as being dysregulated. Additionally, gene
expression levels were manually checked for the predicted off-
targets located within an ORF; no significant difference in gene
expression was detected (Datasets S5 and S6). This supports
the view that the described phenotype is not due to CRISPR off-
targeting.
Induced Emphysema Following a Two-Hit, 2-Wk Lipopolysaccharide
Challenge. Patients with AAT deficiency are subjected to lung
damage when they are exposed to a bacterial infection. Bac-
terial infection leads to a neutrophilic response in the alveoli
and the absence of AAT results in unopposed NE damage. The
resulting emphysema leads to increased pulmonary compliance
and decreased elastance. To determine whether the Serpina1a–e
knockout mouse mimicked the clinical phenotype associated with
this deficiency in humans, we exposed the airways of the mice to a
mild lipopolysaccharide (LPS) challenge. The LPS challenge was
titrated to a dose that wild-type mice could easily overcome but
could hypothetically lead to pathology in Serpina1a–e knockout
mice due to the unabated activity of the secreted NE from the
recruited neutrophils. For the LPS challenge, mice (n = 11–12 per
group) received two doses of LPS on day 1 and day 12 before
characterization of their pulmonary mechanics and lung mor-
phometry at the end of the second week (Fig. 4A). At endpoint,
pulmonary mechanics including maximal pressure–volume (PV)
loops were assessed. The AAT knockout mice had evidence of
Fig. 2. Genomic characterization. A 230-kb genomic region was sequenced by PacBio-LITS for a wild-type C57BL/6J mouse and for a mouse from each
founder line. Overview of the reads mapping to the 230-kb targeted region. (A) Line 7A; (B) line 24B; (C) line 31C. WT, wild type. Red lines indicate the
location of the gRNAs.
Fig. 3. Transcriptomic characterization. The transcriptome of five wild-type
C57BL/6J mice, four mice from line 7A, and four mice from line 24B was
characterized. The animals were aged and gender matched. Differential
gene expression in knockout line vs. wild-type, for (A) line 7A, (B) line 24B.
Solid line, fold change = 2; dashed line, fold change = 4. (C) Genes commonly
dysregulated in lines 7A and 24B. Red, up-regulated genes; green, down-
regulated genes. Pathway analysis for (D) line 7A and (E) line 24B.
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increased lung compliance as indicated by a PV loop that shifted up
and to the left, as would be expected in an emphysematous lung
(Fig. 4B). In addition, the inspiratory capacity of the knockouts was
significantly increased from 0.78 mL to 0.91 mL (Fig. 4C). These
changes were confirmed by measuring the quasistatic compliance
which confirmed a significant increase from 0.066 mL/cmH2O in
the wild-type mice compared with 0.080 mL/cmH2O in the AAT
knockout mice (Fig. 4D). In summary, the pulmonary mechanics
phenotype observed in the knockout mice is very comparable to that
of patients with emphysema.
Next, alveolar morphometry, i.e., the quantitative assessment of
alveolar architecture and structure, was determined. AAT-deficient
patients present with panacinar emphysema, i.e., alveoli and alve-
olar ducts are uniformly enlarged (18). Therefore, a subset of the
mice (n = 7 per group) was analyzed to assess their lung mor-
phometry. Following pulmonary testing, the lungs were filled with a
mixture of agarose and formalin to preserve their internal structure,
lung volume was determined, and tissue sections were stained by
H&E (example shown in Fig. 4E) before quantitative measure-
ments described earlier (19). The total volume showed a trend to-
ward the knockout group having on average a 22% higher volume
(1.7 mL) than the wild-type group (1.4 mL, Fig. S4A) as well as a
higher total surface area (knockout 149.2 μm2, wild type 130.8 μm2,
Fig. S4B). The mean linear intercept, i.e., the mean free distance in
the acinar air space complex, was significantly increased from
43.1 μm for the wild type to 47.05 μm for the knockouts (Fig. 4F).
Taken altogether, these measurements indicate that in the Serpi-
na1a–e knockouts, the alveolar ducts, and alveoli are enlarged,
which recapitulates the clinical characteristics of emphysema.
Spontaneous Emphysema in Unchallenged, Aged Serpina1a–e Knockouts.
Given that a mild LPS challenge was able to recapitulate the hall-
marks of emphysema, we sought to investigate whether emphysema
would naturally develop in these Serpina1a–e knockout mice over
time. Pulmonary mechanics were measured in age-matched, gender-
matched wild-type and knockout mice at 35 (Fig. 5 A and B) and
50 wk of age (Fig. 5 C–F). At 35 wk of age, seven knockout and
10 wild-type animals were analyzed. The PV loop of the knockouts
showed significantly increased compliance compared with their wild-
type controls as evidenced by a shift upwards (Fig. 5A), which is
characteristic of emphysema. Similarly, the quasistatic compliance is
significantly increased in the knockouts compared with the wild types
(Fig. 5B). At 50 wk of age, nine knockout and 8 wild-type animals
were analyzed. Again the PV loops are significantly different (Fig.
5C), and the difference between groups is larger at 50 wk than at
35 wk. The quasistatic compliance of the knockouts is also highly
significantly increased from 0.0696 mL/cmH2O in the wild types to
0.0989 mL/cmH2O in the knockouts (Fig. 5D, P ≤ 0.0001), and the
elastance is significantly decreased (Fig. 5E, P ≤ 0.0002). The re-
sistance is similar in the wild-type controls and the knockouts (Fig.
5F). Taken altogether, these results indicate that the Serpina1a–e
knockout mice spontaneously develop emphysema, with early signs
detectable at 35 wk of age, and at 50 wk of age they present with a
clear emphysematous phenotype.
Cellular and Histological Changes in the Lungs of Serpina1a–e Knockouts.
To determine the mechanism driving the spontaneous emphy-
sema, we analyzed the lung bronchoalveolar lavage fluid (BALF)
of aging mice to see whether there was an active mechanism or
process that could explain the progression of lung disease. We
hypothesized that in the absence of an exogenous insult such
as the LPS or a cigarette-smoke challenge the Serpina1a–e
knockout mice must have an autonomous increase in the
protease/antiprotease imbalance in the lung despite being housed in a
specific pathogen-free (SPF) facility.
Cell counts were determined in the bronchoalveolar lavage
(BAL) of wild-type and Serpina1a–e knockout mice at 8 and 42 wk
of age. Consistent with our hypothesis, neutrophil, monocyte, lym-
phocyte, and macrophage counts were all increased in the 42-wk-old
knockout mice (Fig. 6A), while no difference was detectable in the
8-wk-old mice. We then measured elastase activity in the BALF, to
determine whether the increase in the cell infiltration was sufficient
to increase the protease/antiprotease imbalance (Fig. 6B). These
Fig. 4. Induced emphysema following a two-hit, 2-wk LPS challenge.
(A) Wild-type mice (black triangles) and Serpina1a–e knockout mice (red
circles) were treated twice with lipopolysaccharide (LPS) and presence of
emphysema was assessed 2 wk after the first LPS dose. Pulmonary mechanics
were determined using a flexiVent, parameters assessed include (B) pres-
sure–volume (PV) loop, (C) inspiratory capacity, (D) quasistatic compliance
(wild type n = 11, knockout n = 12). (E) Fixed lung tissue was stained by H&E,
and a representative image from a wild-type mouse is shown here, which
was then used for downstream image analysis. (Scale bar, 100 μm.) The
morphometry was analyzed and the mean linear intercept quantified (F, n =
7 per group). The y axis is truncated in C, D, and F. Error bars represent the
SEM. Statistical significance was determined by two-tailed unpaired t test,
except for the PV loop (two-way ANOVA).
Fig. 5. Spontaneous emphysema in unchallenged, aged Serpina1a–e knock-
outs. Pulmonary mechanics were assessed using a flexiVent in 35-wk-old (A and
B, wild type n = 10, knockout n = 7) and 50-wk-old (C–F, wild type n = 9,
knockout n = 8) wild-typemice (black triangles) and Serpina1 knockoutmice (red
circles). Key parameters assessed include pressure–volume (PV) loop (A and C)
and quasistatic compliance (B and D). Additional parameters include elastance
(E) and resistance (F). The y axis is truncated in B, D, and E. Error bars represent
the SEM. Statistical significance was determined by two-tailed unpaired t test,
except for the PV loops (two-way ANOVA).
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results also indicate an increase in elastase activity with age, where
in the 8-wk cohort, there was a 2.2-fold difference between wild-
type and knockout groups (P < 0.0043), and this difference was
increased to 5.7-fold in the 42-wk cohort (P < 0.0011). Finally,
scanning electron microscopy was performed on the fixed lungs of
70-wk-old mice to confirm the structural changes of the alveoli as a
result of the spontaneous age-dependent emphysema. The images
obtained demonstrate enlargement of the alveolar ducts and alveoli
in Serpina1a–e knockouts (Fig. 6 C and D).
Discussion
The Serpina1a–e null mouse model described in this report was
generated by disrupting five highly homologous gene paralogs
through the targeting of exon 2 using a combination of four
gRNAs. This was achieved three times independently to give rise
to three mouse lines. The genes were disrupted in some cases by
creating large genomic excisions of up to 90,000 bp, but in some
other cases the genomic alterations were more difficult to pin-
point, due to the very high degree of homology of the paralogs.
The null status of the mouse lines was therefore confirmed by
transcriptome analysis, as NMD would occur when a frameshift-
causing alteration of exon 2 would be created. Indeed in lines A
and C, transcripts were highly significantly reduced; however, in
line B transcripts were detected at unchanged levels for Serpina1b.
It is unclear why NMD does not occur in this instance. The ge-
nomic sequence of Serpina1b in line B was precisely characterized,
it is a 73-bp excision linked to gRNA#2, which indeed induces a
frameshift. Translational predictions indicate the potential gen-
eration of a truncated, 105-residue long protein.
The Serpina1a–e null mouse model presented here was gen-
erated by zygote injections using CRISPR/Cas9 targeting, which
resulted in three founders with a biallelic quintuple gene knock-
out, highlighting the efficiency and robustness of this technol-
ogy. This characterization is supported by genomic, transcriptomic,
protein, and physiological data. The animals spontaneously de-
velop emphysema with age, as shown by pulmonary mechanics, a
phenotype consistently observed in all generations of three in-
dependent lines. Here we report that the mechanism underlying
this phenotype is due to an increase in the cellular infiltrates of
these mice as they age, which leads to an increase in the elastase
activity in the BAL. This in turn results in increased alveolar wall
and elastin fiber degradation in the face of a lower antielastase
capacity in the Serpina1a–e knockout mice. It is possible that in
the absence of AAT, the elastin degradation products lead to
further recruitment of cells into the lungs and amplifies this
degenerative process in a feedforward loop that leads to irreversible
lung damage over time. This increased recruitment of cellular in-
filtrates in AAT-deficient lungs is supported by evidence doc-
umenting the consequence of increased pulmonary neutrophil
elastase activity (20, 21) and of elastin breakdown products in AAT
deficiency (22–24). This phenotype models α-1 antitrypsin de-
ficiency lung disease, and should prove extremely valuable to the
preclinical development of novel therapeutics for this disease that
affects about 100,000 individuals in the United States and millions
worldwide. This unique model may allow a precise dissection of the
disease mechanism and bring further insight into the genetic
pathways linked to the pathology. Additionally, the current clinical
endpoint for therapeutic candidates is serum protein levels of
11 μM, a threshold defined through genotype/phenotype studies.
However, studies using this animal model may allow further re-
finement of this threshold, and the definition of alternate end-
points. Finally, this murine strain constitutes the ideal genetic
background in which to introduce the most common human mu-
tation associated with α-1 antitrypsin deficiency, the Z form of the
protein (Z-AAT). Currently ongoing, this work will result in a
mouse model that will genetically and phenotypically recapitulate
two components of the human disease: a loss of function in the
lungs and a gain of function in the liver. The generation of this
model will support the preclinical development of genome editing
therapeutics for α-1 antitrypsin deficiency.
It is well established that patients with α-1 antitrypsin deficiency
are more likely to develop emphysema and/or develop it earlier if
they are exposed to environmental inhalants, which include smoking
(active or passive) and occupational exposure (25–27). This first
animal model of α-1 antitrypsin deficiency will therefore be highly
relevant to further investigate those findings. Beyond the scope of
α-1 antitrypsin, this mouse model more broadly constitutes a unique
model in which to study emphysema. It is a genetic model of em-
physema, not one based on developmental impairment of alveola-
rization, or reliant upon administration of elastase or other
proteinases. It may therefore be used to test factors that influence
development of postnatal or age-related emphysema. For example,
the model might enable the investigation of occupational exposure
to untested air particulates, smoking, and smoke exposure, as well
as new behaviors such as vaping. In conclusion, this mouse model
may have a significantly impact on preventive health for the
α-1 antitrypsin patient community, but also for the COPD pop-
ulation at large, and constitutes a significant step forward for
COPD research.
Materials and Methods
Animal Experiments. The institutional animal care and use committee at the
University of Massachusetts Medical School approved all animal experiments.
Further information is provided in SI Materials and Methods.
Design and Validation of Guide RNAs. National Center for Biotechnology In-
formation (NCBI) blast search was used to identify conserved regions within
the mouse Serpina1 paralogs. CRISPR/Cas9 target sites present in all isoforms
and with low predicted off-target activity were identified using the Bio-
conductor software package CRISPRseek (28). Four CRISPR/Cas9 target
sequences were selected that are conserved in each of the mouse Serpina
paralogs.
ELISA. AAT levels in serum samples were quantified by direct ELISA as de-
scribed (29). Briefly, serum proteins were immobilized in each well, and AAT
was detected by incubating with a polyclonal goat anti-mouse AAT antibody
(GA1T-90A-Z, ICL), followed by incubation with an HRP-conjugated rabbit
anti-goat antibody (ICL) and a peroxidase substrate (KPL Scientific). OD450nm
was read and a four-parameter logistic model was fit to the standard curve
(RS-90A1T, ICL); subsequently, AAT concentration of the unknown samples
was derived. Samples were run in technical triplicates.
Targeted Genome Sequencing. A 230-kb region of chromosome 12
(chr12:103,726,970–103,959,013) was sequenced by PacBio-large insert targeted
sequencing (PacBio-LITS), following a protocol adapted from ref. 30. Briefly, high
molecular weight gDNA was isolated from fresh liver tissue of adult mice (Ge-
nomic-tip 500, Qiagen), sheared to ∼6 kb (g-TUBE, Covaris), preamplified,
Fig. 6. Cellular and histological changes in the lungs of Serpina1a–e
knockouts. (A) Cell counts in the BAL (bronchoalveolar lavage) including
neutrophils (black), monocytes (gray), lymphocytes (red), and macrophages
(white) were determined at 8 wk and 42 wk of age (n = 5 per group).
(B) Relative elastase activity in bronchoalveolar lavage fluid (BALF) was
quantified at 8 wk and 42 wk of age (n = 5 per group). Alveolar structure
was determined at 70 wk of age by scanning electron microscopy (C and D).
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hybridized with custom probes (Roche Nimblegen) designed based on mm10/
GRCm38 for target enrichment by bead capture, and the captured libraries were
amplified. Finally, SMRT libraries were constructed and sequenced on a PacBio
instrument at the Yale Center for Genome Analysis. Raw reads were broken into
separate subreads after removing adapters and trimming away low-quality re-
gions. PacBio sequencing generated >640,000 subreads for each sample. Sub-
reads were aligned to the 230-kb target region by Burrows–Wheeler aligner
(BWA)-maximal exact matches. Using Canu (31), all the reads with high coverage
(>30) are assembled locally into contigs.
Additionally, TLA was performed on line B as described earlier (32).
Splenocytes were isolated from a wild-type mouse and a knockout mouse
from line B and sent to Cergentis B.V. for TLA analysis. Briefly, DNA was
cross-linked, fragmented, and religated. Primer pairs complementary to se-
quences of each Serpina1 paralog were then used to amplify the sur-
rounding loci. PCR products were purified and library was prepped using the
Illumina NexteraXT protocol and sequenced on an Illumina sequencer. Reads
were mapped using BWA’s Smith–Waterman (SW) alignment tool and
mouse mm10 genome version.
RNA-Seq. Total RNA was isolated from snap-frozen liver tissue of 10-wk-old
male mice using TRIzol (Life Technologies) following the manufacturer’s
instructions. Barcoded libraries were sequenced as 50-nt single end reads on an
Illumina HiSEq 4000 instrument at the Beijing Genomics Institute. After
sequencing, the raw reads were filtered, which includes removing adapter se-
quences, contamination, and low-quality reads. RNA-Seq generated >50 million
clean reads for each sample. Using TopHat2 (33), at least 70% of the clean reads
mapped at a single location of the mouse reference genome (mm10) for each
replicate sample. Normalization and differential expression gene analysis were
performed with HTSeq-count (34) and DESeq2 (35) software packages. Pathway
analysis was performed as described in ref. 36.
FlexiVent. Measurements of pulmonary mechanics were performed using
forced oscillometry (flexiVent system; SCIREQ). Respiratory mechanics were
obtained and calculated using flexiWare software (SCIREQ) as previously
described (37).
Morphometry. Immediately following measurements of lung mechanics
(flexiVent), lungs were harvested for morphometric analysis as previously
described (19, 38).
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